HUE028878T2 - CLEC14A inhibitorok - Google Patents
CLEC14A inhibitorok Download PDFInfo
- Publication number
- HUE028878T2 HUE028878T2 HUE10757617A HUE10757617A HUE028878T2 HU E028878 T2 HUE028878 T2 HU E028878T2 HU E10757617 A HUE10757617 A HU E10757617A HU E10757617 A HUE10757617 A HU E10757617A HU E028878 T2 HUE028878 T2 HU E028878T2
- Authority
- HU
- Hungary
- Prior art keywords
- clec14a
- antibody
- inhibitor
- compound
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (14)
1, C LEG 14 A inhibitora manor analoge ne 2 is gát Hsában történő alkalmazásra egy egyénben, ahol az inhibitor egy olyan antitest, amely specif! kusan kötődik a CLEC14.Ô poiipföpticihez vagy ahol az inhibitor egy si RNS molekula, egy antiszensr moi eke la rag y a CLEC14A polinukleotidra specifikus ribozim, vagy nevesett siMJS molekulát kódoló poilnukleotid vagy vektor, antiszensz molekula vagy rifcozim.
2, hz. 1. igénypont s zerinti alkalma zásra való CLECiih inhibitor, ahoi az antitest, specifikusan kötődik az érett CLEC14Ä poiipeptid entraeeliuláris doyenjéhez.
3, Az 1, vagy 2. igénypont szerinti alkalmazásra való CLEG14A inhibitor, ahol az antitest egy monoklónális antitest, egy human!zárt antitest vagy egy egyiánch antitest.
4, Vegyület, amely tartalmaz (ij egy antitestet, amely szelektíven kötődik a CLEC1iá poiipsptidhez és (ü) egy cltotoxi kas egységet, egy egyénben tumor angigenezis gátlásában történő alkalmazásra.
5, A 4, igénypont szerinti alkalmazásra való vegyül et, ahoi, a cltetőzikos egységet egy közvetlenül citotoxikus kemoterápiás szer, egy közvetlenül extotoxikus poiipeptid, egy eiogyogyszert cltotoxikus gyógyszerré alakítani képes egység, egy r ad o s z e rn: i 11 z á 1 ő, egy közvetlenül cltoroz 1 kus nukleinsav, egy közvetlenül citotoxikus polipeptidefc. kódoló nukleinsav molekula, egy elögyőgyszert citotoxikus g y ô g y s z e.r r é a 1 a k i.t. a n i képe s, e n z ima t i k o s a k.t i v i t á s s a 1 rendelkező polIpepnidet kódoló nukleinsav molekula, vagy egy radioaktiv atom közül választjuk, ahol adott esetben a radioaktiv atom a fősz .for-32., jod-125, jód-131, ind lugs™ 111, róni um··· 18 6, rénium-188 vagy ittrxum-áO ,
6, Az 1. - 5. igénypontok bármelyike szerinti alkalmazásra való inhibitor vagy vegyület, ahol az inhibitort vagy a vagyöletét olyan gyógyszerként formulazzak, amely tartalmaz továbbá legalább egy további rákellenes szert.
7. · Az 1, - 5, igénypontok bármelyike ere rit ti alkalmazásra való inhibitor vagy vegyület, ahol at egyén az, akinek legalább egy további rákellenes start adónk,
8. A 6. vagy 7. igénypont szer inti. alkalmazásra való inhibitor vagy vegyület, ahol a legalább egy további, rákellenes szert a oiszplafeín; karbopiatín; 5-fiuorouraci1; paclitaxel ; mitomycin C ; doxorubicin; gemcitabine; torra der; pemetrexeä; methotrexát; i rinotekan, fluorouraci 1. és leukovorin; ozalxplatin, 5-fluorouracil és leukovorin; és paclitaxel és karbopiatín kőről választjuk.
9,. Vegyület, amely tartalmat (í} egy antitestet, amely szeieativen kötődik a CLECliA poiipeptidher és ( A1 ; egy detektálható egységet., egy egyén, testében, tumor neovasrkulatúra képalkotásához való alkalmazásra,
10, A 9. igénypont szerinti alkaimarásra való vegyület, amely tartalmazza továbbá a vegyület helyének detektálását az egyénben,
11, A 9. vagy IQi igénypont szerinti alkalmazásra való vegyület, ahol a detektálható egység a következőket tartalmazza;: lód-· 12 3, jód-131:, indium--111 , tluor-1 9, szénié, ni rrögén-15; oxrgén~l7, technécium---99m, gadolinium, mangán vagy vas.
12, Bármely előzd Igénypont szerinti alkalmazásra való inhibitor vagy vagyaién, ahol az egyén egy ember,
13, Bármely előző igénypont szerinti, alkalmazásra való inhibitor vagy vegyület, ahol az egyénnek szilárd tumora van, például vastagbél, végnél,. petefészek, mád;, hólyag, prosztata, mell, vese, hasnyálmirigy, gyomor, nyelőcső, tüdő vagy pa3tsmirxgy szilárd daganata.
14, A 13». igénypont szerinti alkalmazásra való inhibitor vagy ve gyúr et, ahol a szilárd tumor nem tüdő túrnom és./ vagy nem végbél tumor.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23958409P | 2009-09-03 | 2009-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE028878T2 true HUE028878T2 (hu) | 2017-01-30 |
Family
ID=43333027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE10757617A HUE028878T2 (hu) | 2009-09-03 | 2010-09-03 | CLEC14A inhibitorok |
Country Status (8)
Country | Link |
---|---|
US (1) | US9255148B2 (hu) |
EP (1) | EP2473529B1 (hu) |
JP (1) | JP5962996B2 (hu) |
AU (1) | AU2010290989B2 (hu) |
CA (1) | CA2810119C (hu) |
ES (1) | ES2567030T3 (hu) |
HU (1) | HUE028878T2 (hu) |
WO (1) | WO2011027132A1 (hu) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013187556A1 (en) * | 2012-06-14 | 2013-12-19 | Scripps Korea Antibody Institute | Novel antibody specific for clec14a and uses thereof |
GB201501004D0 (en) * | 2015-01-21 | 2015-03-04 | Cancer Rec Tech Ltd | Inhibitors |
JP7501991B2 (ja) * | 2016-03-15 | 2024-06-18 | キャンサー・リサーチ・テクノロジー・リミテッド | 抗体及び関連分子並びにその使用 |
US20190085081A1 (en) * | 2016-03-15 | 2019-03-21 | Cancer Research Technology Limited | Chimeric antigen receptor |
KR102201992B1 (ko) * | 2016-09-08 | 2021-01-12 | 주식회사 우리기술 | clec14a에 특이적으로 결합하는 탈당화 항체 및 그 용도 |
CN113332448B (zh) * | 2017-03-17 | 2023-08-08 | 浙江孚诺医药股份有限公司 | 肿瘤靶向多肽、制备方法及其应用 |
GB202219154D0 (en) | 2022-12-19 | 2023-02-01 | Metacurum Biotech Ab | Antibodies and uses thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
WO1996006641A1 (en) | 1994-08-29 | 1996-03-07 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US5716081A (en) | 1996-03-11 | 1998-02-10 | Automotive Products (Usa), Inc. | Spring clip for quick connect coupling |
US5846220A (en) | 1996-04-30 | 1998-12-08 | Medtronic, Inc. | Therapeutic method for treatment of Alzheimer's disease |
ATE374248T1 (de) | 1996-06-27 | 2007-10-15 | Vlaams Interuniv Inst Biotech | Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030108983A1 (en) | 1997-09-17 | 2003-06-12 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6225118B1 (en) | 1997-10-01 | 2001-05-01 | Biocure Limited | Multicellular in vitro assay of angiogenesis |
US6894148B2 (en) | 1997-11-12 | 2005-05-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20020015950A1 (en) | 1999-07-07 | 2002-02-07 | Karen Anne Jones | Atherosclerosis-associated genes |
ATE348108T1 (de) | 1999-03-08 | 2007-01-15 | Genentech Inc | Methode zum nachweis von tumoren |
NZ523206A (en) | 1999-08-31 | 2004-12-24 | Genentech Inc | Antibodies that bind to tumor gene sequences |
US7695959B2 (en) | 2000-05-23 | 2010-04-13 | Neurologix, Inc. | Glutamic acid decarboxylase (GAD) based delivery systems |
EP1309620A2 (en) * | 2000-06-23 | 2003-05-14 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
AU2002223784B2 (en) | 2000-11-06 | 2007-01-18 | Cancer ResearchTechnology Limited | Imaging, diagnosis and treatment of disease |
JP2004531249A (ja) * | 2001-02-14 | 2004-10-14 | プロテイン デザイン ラブス インコーポレイティド | 血管新生の診断方法、組成物、及び血管新生モジュレータのスクリーニング方法 |
US20040033495A1 (en) * | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
WO2003101283A2 (en) | 2002-06-04 | 2003-12-11 | Incyte Corporation | Diagnostics markers for lung cancer |
EP1565491B1 (en) | 2002-11-20 | 2010-03-31 | Cancer Research Technology Limited | Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis |
US20060148695A1 (en) | 2005-01-03 | 2006-07-06 | National Cheng Kung University | Novel angiogenic composition and use thereof |
US8293710B2 (en) | 2005-01-03 | 2012-10-23 | Blue Blood Biotech Corp. | Method for treating wounds using an EGF-like domain of thrombomodulin |
CA2601677A1 (en) * | 2005-03-11 | 2006-09-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
JP4832515B2 (ja) * | 2005-06-09 | 2011-12-07 | ブルー ブラッド バイオテック コーポレーション | 創傷治癒用の組成物及びその使用 |
-
2010
- 2010-09-03 JP JP2012527386A patent/JP5962996B2/ja not_active Expired - Fee Related
- 2010-09-03 HU HUE10757617A patent/HUE028878T2/hu unknown
- 2010-09-03 EP EP10757617.5A patent/EP2473529B1/en active Active
- 2010-09-03 ES ES10757617.5T patent/ES2567030T3/es active Active
- 2010-09-03 CA CA2810119A patent/CA2810119C/en not_active Expired - Fee Related
- 2010-09-03 AU AU2010290989A patent/AU2010290989B2/en not_active Ceased
- 2010-09-03 WO PCT/GB2010/001689 patent/WO2011027132A1/en active Application Filing
- 2010-09-03 US US13/393,921 patent/US9255148B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP5962996B2 (ja) | 2016-08-03 |
ES2567030T3 (es) | 2016-04-19 |
AU2010290989A1 (en) | 2012-03-15 |
US20120276000A1 (en) | 2012-11-01 |
EP2473529B1 (en) | 2016-02-10 |
WO2011027132A1 (en) | 2011-03-10 |
JP2013503842A (ja) | 2013-02-04 |
CA2810119A1 (en) | 2011-03-10 |
EP2473529A1 (en) | 2012-07-11 |
US9255148B2 (en) | 2016-02-09 |
CA2810119C (en) | 2018-10-23 |
AU2010290989B2 (en) | 2016-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6196338B2 (ja) | 診断および治療のための腫瘍関連抗原の同定 | |
US10479997B2 (en) | Compositions and methods for diagnosis and treatment of prostate cancer | |
DK2513146T3 (en) | Antibodies against ROR1 capable of inducing cell death by CLL | |
EP2473529B1 (en) | Clec14a inhibitors | |
UA128387C2 (uk) | Антитіло до lag3 | |
JP6628290B2 (ja) | 阻害剤 | |
US20180010132A1 (en) | Inhibition of prmt5 to treat mtap-deficiency-related diseases | |
US20060024233A1 (en) | Use of biomolecular targets in the treatment and visualization of brain tumors | |
KR101886890B1 (ko) | 항인간 ccr7 항체, 하이브리도마, 핵산, 벡터, 세포, 의약 조성물 및 항체 고정화 담체 | |
WO2016133059A1 (ja) | Fstl1を利用した抗がん剤・転移抑制剤およびその併用剤 | |
WO2009044158A2 (en) | Inhibitors and uses | |
JP2004537282A (ja) | 脳腫瘍の処置及び可視化における生体分子標的の使用法 | |
WO2016092301A1 (en) | Vascular targeting |